Ambion Announces Continued Alliance With Wyeth

Ambion Diagnostics, a division of Ambion, has entered into a new agreement with Wyeth Pharmaceuticals to continue its alliance in the development and supply of cGMP-grade RNA that will be incorporated as a component in Wyeth's innovative vaccine program. Ambion Diagnostics will manufacture RNA transcripts according to QSR guidelines and will supply the material at a scale sufficient to meet Wyeth's requirements for Phase I/II clinical trials.

Austin dBusiness News (http://austin.dbusinessnews.com/shownews.php?newsid=13978&type_news=latest)